A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01292603 |
|
Recruitment Status :
Completed
First Posted : February 9, 2011
Results First Posted : December 15, 2015
Last Update Posted : December 18, 2017
|
Sponsor:
Hoffmann-La Roche
Information provided by (Responsible Party):
Hoffmann-La Roche
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
This randomized, parallel-group, multi-center study will compare the pharmacokinetics and safety of subcutaneous administration of MabThera (rituximab) versus intravenous MabThera in combination with chemotherapy in previously untreated patients with chronic lymphocytic leukemia (CLL). The study consists of 2 parts. In part 1, patients who have previously received 4 cycles of intravenous MabThera will receive in Cycle 5 intravenous MabThera and in Cycle 6 subcutaneous MabThera. In part 2, patients will be randomized to receive either 6 cycles of intravenous MabThera, or 1 cycle of intravenous MabThera and 5 cycles of subcutaneous MabThera. Additionally, all patients will receive chemotherapy (fludarabine and cyclophosphamide) on Days 1-3 or Days 1-5 of every cycle. The anticipated time on study drug is 24 weeks.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Lymphocytic Leukemia, Chronic | Drug: Cyclophosphamide Drug: Fludarabine Drug: rituximab [MabThera] | Phase 1 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 240 participants |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | An Adaptive, Comparative, Randomized, Parallel-group, Multi Center, Phase Ib Study of Subcutaneous (SC) Rituximab Versus Intravenous (IV) Rituximab Both in Combination With Chemotherapy (Fludarabine and Cyclophosphamide), in Patients With Previously Untreated CLL |
| Actual Study Start Date : | April 18, 2011 |
| Actual Primary Completion Date : | May 7, 2014 |
| Actual Study Completion Date : | November 17, 2017 |
Resource links provided by the National Library of Medicine
Drug Information available for:
Rituximab
| Arm | Intervention/treatment |
|---|---|
| Experimental: 1 |
Drug: Cyclophosphamide
Days 1-3 or Days 1-5 of cycles 1-6 Drug: Fludarabine Days 1-3 or Days 1-5 of cycles 1-6 Drug: rituximab [MabThera] After 4 cycles of intravenous MabThera without experiencing grade 3 or 4 infusion-related reactions. patients will receive 1 additional cycle of intravenous MabThera and 1 cycle of subcutaneous MabThera. |
| Experimental: 2 |
Drug: Cyclophosphamide
Days 1-3 or Days 1-5 of cycles 1-6 Drug: Fludarabine Days 1-3 or Days 1-5 of cycles 1-6 Drug: rituximab [MabThera] 6 cycles of intravenous MabThera |
| Experimental: 3 |
Drug: Cyclophosphamide
Days 1-3 or Days 1-5 of cycles 1-6 Drug: Fludarabine Days 1-3 or Days 1-5 of cycles 1-6 Drug: rituximab [MabThera] One cycle of intravenous MabThera, followed by 5 cycles of subcutaneous MabThera |
Primary Outcome Measures :
- Part 1: Subcutaneous Rituximab Dose Resulting in Trough Concentration (Ctrough) Levels Non-Inferior to Intravenous Rituximab [ Time Frame: Pre-dose and post-dose (15 minutes to end of infusion) on Day 1 and on Days 2, 5, 11 and 15 of Cycle 5 and Pre-dose, Post-dose on Days 2, 3, 5,11, 15 and 29 of Cycle 6; Pre-dose was taken 2 hours prior rituximab dose ]Ctrough is defined as the trough or minimum serum concentration. Pharmacokinetic parameters for rituximab were assessed during Cycles 5 (IV rituximab) and 6 (SC rituximab). Rituximab pharmacokinetic (PK) data from Part 1 were integrated into a population PK model using parametric, nonlinear, mixed-effects modelling. Rituximab IV 500 mg/m^2 administered once every 4 weeks was compared to fixed doses of rituximab SC between 1400 mg and 1870 mg. The dose selection was performed on Ctrough concentrations at Cycle 5 (pre-dose Cycle 6). A test of the probability of success was applied to each of the 100 replicates, and the percentage of replicates with a positive test corresponded to the probability of success of the trial.
- Part 2: Rituximab C Trough Levels at Cycle 5 [ Time Frame: +/- 25hours around the 28th day post the 5th Cycle of Rituximab administration ]Ctrough is defined as the trough or minimum serum concentration in a given cycle of treatment. The objective of Part 2 was to demonstrate the comparability of the observed Ctrough of rituximab SC 1600 mg and rituximab IV 500 mg/m2 at Cycle 5, as assessed by a non-inferiority test with a lower boundary of at least 0.8 for the 90% CI.
Secondary Outcome Measures :
- Part 2: Observed Area Under the Serum Concentration-Curve (AUC) of Rituximab at Cycle 6 [ Time Frame: Rituximab IV arm: pre-dose, post-dose and on Days 2, 3, 8 ,15, 29 of Cycle 6; Rituximab SC arm: pre-dose, and on Days 2, 3, 8 ,15, 29 of Cycle 6 ]
AUC values were calculated by numerical integration using the linear trapezoidal rule. AUC levels were analyzed using the model below:
Ln(AUC) = μ + τi + BlTLij + εij wherein, Ln is the natural log, μ denotes the overall mean effect, τi the effect in each treatment group, BlTLij the tumor load at baseline for each patient and εij a random error variable with normal distribution and mean 0. The treatment effect therein was based on a contrast statement in the model to calculate 90 % confidence intervals for ln(AUC SC)- ln(AUC IV).
- Part 2: Maximum Observed Concentration (Cmax) of Rituximab at Cycle 6 [ Time Frame: Rituximab IV arm: pre-dose, post-dose and on Days 2, 3, 8 ,15, 29 of Cycle 6; Rituximab SC arm: pre-dose, and on Days 2, 3, 8 ,15, 29 of Cycle 6 ]Cmax was obtained directly from the measured concentration-time curves. The concentration-time curve is the result of time points of blood sampling and its measured concentration of rituximab in the blood samplings.
- Part 2: Time to Cmax (Tmax) of Rituximab at Cycle 6 [ Time Frame: Rituximab IV arm: pre-dose, post-dose and on Days 2, 3, 8 ,15, 29 of Cycle 6; Rituximab SC arm: pre-dose, and on Days 2, 3, 8 ,15, 29 of Cycle 6 ]Multiple blood samples were obtained at pre-dose, post-dose and on Days 2, 3, 8 ,15, 29 of Cycle 6 in Rituximab IV arm, and at pre-dose, and on Days 2, 3, 8 ,15, 29 of Cycle 6 in Rituximab SC arm and time to peak plasma concentration of rituximab was determined.
- Part 2: Terminal Half-Life of Rituximab at Cycle 6 [ Time Frame: Rituximab IV arm: pre-dose, post-dose and on Days 2, 3, 8 ,15, 29 of Cycle 6; Rituximab SC arm: pre-dose, and on Days 2, 3, 8 ,15, 29 of Cycle 6 ]The terminal half-life (t1/2) of rituximab is defined as the time required for the plasma concentration of rituximab to reach half of its original concentration.
- Part 1: Percentage of Participants and Nurses Recording a Preference For Either SC or IV Administration [ Time Frame: Days 4 to 5 in Cycle 6 ]In part 1 of the trial, upon completion of dosing in cycle 6, participants and their treating nurses were asked whether they have a preference of dosing route, IV vs SC
- Part 2: Physician/Nurse Opinion on Time Savings With Rituximab SC Compared With Rituximab IV [ Time Frame: Days 4-5 in Cycle 6 ]
Physicians and nurses who administered rituximab were asked to answer the following question: " If used in routine practice, on average, how much staff time could be saved with each administration of rituximab SC as compared to rituximab IV? (Please do not consider the time needed for the first IV administration, consider only the subsequent ones). Percentage of participants with specified answers were reported.
- A- Less than 1 hour
- B- At least 1 hour but less than 2 hours
- C- At least 2 hours but less than 3 hours
- D- At least 3 hours but less than 4 hours
- E- 4 or more hours
- Part 2: Physician/Nurse Opinion on Convenience of Rituximab SC Compared With Rituximab IV [ Time Frame: Days 4-5 in Cycle 6 ]
Physicians and nurses who administered rituximab were asked to answer the following question: Which formulation of rituximab (SC or IV) do you think is more convenient? with pre-specified responses as below. Percentage of participants with specified answers were reported.
- A - Rituximab SC is much more convenient.
- B - Rituximab SC is a little more convenient.
- C - Both formulations are equally convenient.
- D - Rituximab IV is a little more convenient.
- E - Rituximab IV is much more convenient
- Part 1: Percentage of Participants With Anti-Rituximab Antibodies [ Time Frame: Predose at Cycles 5 and 6 and at each follow up visit until 24 months after the last dose ]Blood samples for the assessment of antibodies against rituximab (HACAs) were drawn pre-dose at Cycle 5 and Cycle 6 in Part 1 and at each follow up visit until 24 months after the last dose.
- Part 2: Percentage of Participants With Anti-Rituximab Antibodies [ Time Frame: Day 0 of Cycle 1 and Day 1 of Cycles 1, 2, 3, 4, 5, and 6 and at each follow-up visit until 24 months after the last dose of rituximab. ]In Part 2, samples for the HACA assay were collected at each treatment cycle prior to the administration of rituximab and at each follow-up visit until 24 months after the last dose of rituximab.
- Part 1: Total Cluster Differentiation19 Positive (CD19+) B-Cell Counts by Visit [ Time Frame: Day 1 of Cycles 5 and 6 and Follow-up Days 28 and 56 and Follow-up Visits at Months 3, 6, 9, 12, 15,18, 21 and 24 ]CD 19 is a surface antigen (protein) present on B-lymphocytes.
- Part 1: Percentage of Participants With Total B-Cell Depletion by Visit [ Time Frame: Day 1 pre-dose of Cycles 5 and 6 and Follow-up Days 28 and 56 and Follow-up Visits at Months 3, 6, 9, 12, 15, 18, 21 and 24 ]Total B-cell depletion (normal B-cell plus Malignant B-cell depletion) was defined for each individual participant when the sum of CD5-/CD19+ (normal B-cells) and CD5+/CD19+ (malignant B-cells) cell counts decreased below 80 cells/μL.
- Part 2: Total CD19+ B-Cell Counts by Visit [ Time Frame: Cycle 1 pre-dose, 60 minutes post-dose, Days 2 and 3 in Cycle 2, day 1 pre-dose in Cycles 3, 4, 5 and 6, Follow-up Days 28 and 56, and Follow-up Visits at Months 3, 6, 9, 12, 15, and 18 and Withdrawal Visit ]CD 19 is a surface antigen (protein) present on B-lymphocytes.
- Part 2: Percentage of Participants With Total B-Cell Depletion by Visit [ Time Frame: Cycle 1 Pre-dose, 60 minutes post-dose, Days 2 and 3 in Cycle 2, day 1 in Cycles 3, 4, 5 and 6, Follow-up Days 28 and 56, and Follow-up Visits at Months 3, 6, 9, 12, 15, and 18 and Withdrawal Visit ]Total B-cell depletion (normal B-cell plus Malignant B-cell depletion) was defined for each individual participant when the sum of CD5-/CD19+ (normal B-cells) and CD5+/CD19+ (malignant B-cells) cell counts decreased below 80 cells/μL.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Adult patients, >/=18 years of age
- Patients with treatment-requiring chronic lymphocytic leukemia (CLL)
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Life expectancy >6 months
Exclusion Criteria:
- Transformation to aggressive B-cell malignancy
- History of other malignancy unless the patient was treated with curative intent and has been in remission for more than 5 years prior to enrolment
- HIV or Hepatitis B positive unless clearly due to vaccination
- Inadequate liver or renal function
- Any coexisting medical or psychological condition that would preclude participation in the required study procedures
Additional exclusion criterion for Part 1:
- Any previous treatment for CLL except for up to 4 cycles of rituximab IV in combination with FC chemotherapy as first-line treatment for CLL
Additional exclusion criterion for Part 2:
- Any previous treatment for CLL
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01292603
Show 84 Study Locations
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
| Study Director: | Clinical Trials | Hoffmann-La Roche |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Hoffmann-La Roche |
| ClinicalTrials.gov Identifier: | NCT01292603 History of Changes |
| Other Study ID Numbers: |
BO25341 2010-021380-32 ( EudraCT Number ) |
| First Posted: | February 9, 2011 Key Record Dates |
| Results First Posted: | December 15, 2015 |
| Last Update Posted: | December 18, 2017 |
| Last Verified: | December 2017 |
Additional relevant MeSH terms:
|
Leukemia Leukemia, Lymphoid Leukemia, Lymphocytic, Chronic, B-Cell Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Leukemia, B-Cell Cyclophosphamide Fludarabine phosphate Rituximab |
Fludarabine Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Myeloablative Agonists Antimetabolites, Antineoplastic Antimetabolites |